On May 8, 2024, the board of directors of TRACON Pharmaceuticals, Inc. appointed, and the Company entered into an employment agreement (the Agreement") with, David Lazar as Chief Business Development Officer of the Company, effective as of May 7, 2024 (the Effective Date"). Mr. Lazar, age 33, has served as the Chief Executive Officer of OpGen, Inc. (NASDAQ: OPGN) since April 2024. Mr. Lazar has also served as the Chief Executive Officer of Titan Pharmaceuticals Inc. (NASDAQ: TTNP) since August 2022, where he also served as a director and board chairman from August 2022 until October 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +6.35% | +24.07% | -61.74% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.74% | 3.59M | |
+2.52% | 92.1B | |
-3.16% | 37.92B | |
-12.49% | 32.97B | |
+74.97% | 27.92B | |
-11.82% | 16.14B | |
-0.16% | 14.1B | |
-11.18% | 11.66B | |
+171.57% | 10.29B | |
-50.45% | 9.99B |
- Stock Market
- Equities
- TCON Stock
- News TRACON Pharmaceuticals, Inc.
- Tracon Pharmaceuticals, Inc. Appoints David Lazar as Chief Business Development Officer